Figure 7.

Complement dependent lysis and C3b deposition on primary human B cells. CDC and C3b deposition were compared for primary human B cells derived from healthy donor blood upon treatment with 20 µg/ml Rituximab (RTX), Ofatumumab (OFA), or Obinutuzumab (OBI) in absence (white) or presence of 20% human serum (NHS, black bars) or heat-inactivated serum (HIS, gray bars) for 30 min at 37°C. (A) Exemplary dot plots of CD19 and DAPI staining. (B) Quantification of living CD19⁺DAPI^- cells. (C) Quantification of C3b/iC3b deposition on B cells. Bars show mean and standard deviation of n=4 independent experiments using PBMCs from different donors and treated with four human sera each. For statistical analysis, two-way ANOVA and Sidak´s multiple comparison test were applied. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.